Trials / Completed
CompletedNCT06960239
Safety and Efficacy of the Irreversible Electroporation (IRE) System for Adenotonsillar Hypertrophy in Children
Evaluation of the Efficacy and Safety of an Irreversible Electroporation (IRE) System for The Treatment of Upper Airway Obstruction Due to Adenotonsillar Hypertrophy in Children
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- ENTire Medical Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
This is a multi-center, prospective, open-label, traditional feasibility study with a before-after study design. The study is designed to evaluate the safety and efficacy of an Irreversible Electroporation (IRE) System for the treatment of upper airway obstruction due to adenotonsillar hypertrophy in Children.
Detailed description
The purpose of the IRE System is to address the clinical need for reducing the volume of hypertrophic tonsil(s) and adenoid while minimizing side effects and complications. Procedure time will also be reduced. The IRE System is designed to be more comfortable for patients, as it employs a noninvasive procedure using a high voltage pulsed electric field to create irreversible nanopores in the cell membrane, leading to cell death and the reduction of the tonsils and adenoid volume. On basis of these finding and in view of the known safety profile and efficacy of current adeno-tonsillar reduction technologies, the purpose of the current study is to prospectively determine the efficacy and safety of the IRE System in adeno-tonsillar reduction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | IRE System | Irreversible Electroporation (IRE) System for the Treatment of Upper Airway Obstruction due to Adenotonsillar Hypertrophy in Children |
Timeline
- Start date
- 2024-11-14
- Primary completion
- 2025-10-22
- Completion
- 2025-10-22
- First posted
- 2025-05-07
- Last updated
- 2026-03-18
Locations
2 sites across 2 countries: Romania, Uzbekistan
Source: ClinicalTrials.gov record NCT06960239. Inclusion in this directory is not an endorsement.